Robert Garry

The COI Committee determined that Dr. Garry’s financial interest related to Zalgen Labs could directly and significantly affect the conduct and reporting of the research. Dr. Garry, the Principal Investigator of this award, holds an equity interest in Zalgen Labs. Zalgen Labs is directed and co-owned by Dr. Luis M. Branco, and is a subcontractor on the subject grant. This project will advance the preclinical evaluation of Arevirumab, a combination of broadly neutralizing human monoclonal antibodies that has been shown to rescue 100% of nonhuman primates even after delay in the start of treatment to 8 days post-infection, a time when the animals displayed severe hematological and metabolic dysregulation. Researchers will perform dose finding and dosing interval studies, generate Chemistry, Manufacturing and Control (CMC) data and perform preclinical pharmacology and toxicology of Arevirumab in appropriate animal models. At the conclusion of the proposed program there are plans to conduct a clinical evaluation of a first-in-class immunotherapeutic cocktail of human monoclonal antibodies for the prophylactic and post-exposure treatment of Lassa fever. As the Principal Investigator, Dr. Garry has plenary oversight responsibility for the grant project and he will have responsibility for project administration, including subcontractor management and scientific publications. The COI Committee determined that data collection and evaluation at various points of the project could be affected by Dr. Garry’s financial interests.